Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.

Townsend, M

Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. [electronic resource] - Heart (British Cardiac Society) Aug 2004 - e47 p. digital

Publication Type: Journal Article

1468-201X

10.1136/hrt.2004.036236 doi


Antiparkinson Agents--adverse effects
Cabergoline
Ergolines--adverse effects
Fibrosis--chemically induced
Humans
Male
Middle Aged
Parkinson Disease--drug therapy
Pericarditis, Constrictive--chemically induced
Pleura--pathology
Pulmonary Fibrosis--chemically induced